What are you disrupting?

The fabric and landscape of biotech R&D and life sciences in general is going to radically change in 2025 and beyond. Massachusetts is home to about 1000 biotech companies, which all stand to benefit from leaner AI-driven systems. AI agents can now communicate with the molecular, meaning that it requires less scientific expertise to decode complex biological data and get needed answers to important research questions. Unfortunately, at Scriptome.AI, we believe that most science-focused researchers are about to get commoditized, and replaced with agentic systems that can do the work faster, more precisely and with a smile 24/7. When a computational biologist expert is no longer needed to decode complex sequencing data, and this work can be done with an agent, chatbot and LLM, R&D folks should realize that times are a changing and the agents are coming for the jobs. We're all going to be in for a massive, collective humbling later this year, when the available AI tools can run circles around us doing work that took us decades to master through education and training.

We're here building these efficient new AI tools and systems, but also to help R&D folks in biotech upskill in necessary AI skills so they can be gainfully employed and in demand during this exciting period of technological development. The pharma companies showed great progress with AI systems in 2024, but the small biotechs have fallen behind with their implementations and use of AI tools and platforms. These small companies are the life blood of new ideas for therapies in the Commonwealth, and Scriptome.AI is here to ensure that they aren't left behind as the drug development race gets faster and faster with AI.

Find out more and reach out to get your biotech up to speed with an AI strategy and the right tools to remain competitive:

https://scriptome.ai
stu@scriptome.ai

If you're not in biotech, how can we help you?

Stu Angus

Founder